Yoshizue, T.; Brindha, S.; Wongnak, R.; Takemae, H.; Oba, M.; Mizutani, T.; Kuroda, Y.
Antisera Produced Using an E. coli-Expressed SARS-CoV-2 RBD and Complemented with a Minimal Dose of Mammalian-Cell-Expressed S1 Subunit of the Spike Protein Exhibits Improved Neutralization. Int. J. Mol. Sci. 2023, 24, 10583.
https://doi.org/10.3390/ijms241310583
AMA Style
Yoshizue T, Brindha S, Wongnak R, Takemae H, Oba M, Mizutani T, Kuroda Y.
Antisera Produced Using an E. coli-Expressed SARS-CoV-2 RBD and Complemented with a Minimal Dose of Mammalian-Cell-Expressed S1 Subunit of the Spike Protein Exhibits Improved Neutralization. International Journal of Molecular Sciences. 2023; 24(13):10583.
https://doi.org/10.3390/ijms241310583
Chicago/Turabian Style
Yoshizue, Takahiro, Subbaian Brindha, Rawiwan Wongnak, Hitoshi Takemae, Mami Oba, Tetsuya Mizutani, and Yutaka Kuroda.
2023. "Antisera Produced Using an E. coli-Expressed SARS-CoV-2 RBD and Complemented with a Minimal Dose of Mammalian-Cell-Expressed S1 Subunit of the Spike Protein Exhibits Improved Neutralization" International Journal of Molecular Sciences 24, no. 13: 10583.
https://doi.org/10.3390/ijms241310583
APA Style
Yoshizue, T., Brindha, S., Wongnak, R., Takemae, H., Oba, M., Mizutani, T., & Kuroda, Y.
(2023). Antisera Produced Using an E. coli-Expressed SARS-CoV-2 RBD and Complemented with a Minimal Dose of Mammalian-Cell-Expressed S1 Subunit of the Spike Protein Exhibits Improved Neutralization. International Journal of Molecular Sciences, 24(13), 10583.
https://doi.org/10.3390/ijms241310583
